Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo.
Try Elite for Free
Login Sign up free
Home Stock ScreenerScreener ETF ScreenerETF Maps Charts News Groups Insider Futures Forex Crypto Watchlist Portfolio Calendar
Pricing

ETON

Eton Pharmaceuticals Inc

Last Close
53.67
Oct 29 • 3:59 PM ET Dollar change+1.87 Percentage change(3.61%)
Aftermarket Close
54.36
Aftermarket • 7:30 PM ET Dollar change+0.69 Percentage change(1.29%)
Overview Compare Short Interest Financials Options Filings Dilution
Healthcare Drug Manufacturers - Specialty & Generic USA Small NASD
Peers: XERS NBIX ANIP HROW ZVRA TVTX HRMY ASND RYTM SPRB
 | Held by: VTI IWM VXF IWO FYC XPH VTWO SCHA FYX IWC
Scroll to Statements
Index
RUT
Market Cap
1.53B
Enterprise Value
1.54B
Income
12.69M
Sales
105.59M
Book/sh
1.65
Cash/sh
0.94
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
44
IPO
Nov 13, 2018
P/E
141.91
Forward P/E
25.75
PEG
0.24
P/S
14.53
P/B
32.59
P/C
57.16
P/FCF
104.15
EV/EBITDA
72.99
EV/Sales
14.55
Quick Ratio
1.30
Current Ratio
1.52
Debt/Eq
0.63
LT Debt/Eq
0.43
Option/Short
Yes / Yes
EPS (ttm)
0.38
EPS next Y
2.08
EPS next Q
0.31
EPS this Y
210.54%
EPS next Y
91.79%
EPS next 5Y
107.84%
EPS past 3/5Y
21.89% 33.66%
Sales past 3/5Y
55.53% 359.57%
EPS Y/Y TTM
399.54%
Sales Y/Y TTM
81.49%
EPS Q/Q
467.43%
Sales Q/Q
98.59%
Earnings
Nov 05 AMC
EPS/Sales Surpr.
84.40% 38.67%
Insider Own
4.93%
Insider Trans
-30.01%
Inst Own
70.01%
Inst Trans
10.66%
ROA
11.67%
ROE
35.97%
ROIC
19.01%
Gross Margin
57.87%
Oper. Margin
15.63%
Profit Margin
12.02%
SMA20
2.30%
SMA50
-4.43%
SMA200
51.08%
Trades
Shs Outstand
28.29M
Shs Float
27.17M
Short Float
7.15%
Short Ratio
3.40
Short Interest
1.94M
52W High
66.37 -19.14%
52W Low
14.27 276.10%
Volatility
3.72% 4.95%
ATR (14)
2.60
RSI (14)
52.97
Beta
0.88
Rel Volume
0.65
Avg Volume
570.81K
Volume
369,485
Perf Week
7.30%
Perf Month
4.23%
Perf Quarter
15.62%
Perf Half Y
122.51%
Perf YTD
217.39%
Perf Year
193.12%
Perf 3Y
1335.03%
Perf 5Y
831.77%
Perf 10Y
-
Recom
1.00
Target Price
71.50
Prev Close
51.80
Price
53.67
Change %
3.61%
Consensus
Strong Buy
Avg. Price Target
$71.50
Implied Upside
+33.2%
Analysts5incl. previous ratings
Rating Distribution5 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Jul 17, 2026Initiated
CCanaccord Genuity
Buy$60+11.8%
Jan 23, 2025Reiterated
HH.C. Wainwright
Buy$17 → $33-38.5%
Jan 10, 2025Initiated
RILY logoRB. Riley Securities
Buy$21-60.9%
Jan 06, 2025Reiterated
HH.C. Wainwright
Buy$15 → $17-68.3%
Sep 04, 2024Resumed
HH.C. Wainwright
Buy$9-83.2%
May 06, 2024Initiated
CCraig Hallum
Buy$8-85.1%
Oct 14, 2021Resumed
RILY logoRB. Riley Securities
Buy$10-81.4%
Jan 04, 2021Reiterated
HH.C. Wainwright
Buy$20 → $15-72.1%
Sep 20, 2019Initiated
BB. Riley FBR
Buy$13.50-74.8%
Jun 10, 2019Initiated
HH.C. Wainwright
Buy$15-72.1%
Show Previous News
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Krempa DavidChief Business OfficerOct 06 '26Sale55.074,166229,40643,381Oct 06 04:49 PM
Krempa DavidOfficerOct 06 '26Proposed Sale55.074,166229,406Oct 06 04:05 PM
MAIER PAUL VDirectorAug 28 '26Option Exercise3.7850,000189,000109,745Aug 28 04:51 PM
MAIER PAUL VDirectorAug 28 '26Sale59.0750,0002,953,57259,745Aug 28 04:51 PM
MAIER PAUL VDirectorAug 28 '26Proposed Sale59.0750,0002,953,530Aug 28 04:41 PM
Krempa DavidChief Business OfficerAug 24 '26Option Exercise7.3125,000182,75062,025Aug 24 05:19 PM
Krempa DavidChief Business OfficerAug 24 '26Sale65.0725,0001,626,75037,025Aug 24 05:19 PM
Krempa DavidOfficerAug 24 '26Proposed Sale65.0725,0001,626,750Aug 24 04:19 PM
BRYNJELSEN SEANPresident & CEOAug 20 '26Sale60.7091,0225,525,301961,194Aug 20 06:26 PM
BRYNJELSEN SEANPresident & CEOAug 19 '26Sale62.658,978562,4721,052,216Aug 20 06:26 PM
BRYNJELSEN SEANDirectorAug 19 '26Proposed Sale63.43100,0006,343,000Aug 19 10:49 AM
Opaleye Management Inc.10% OwnerJul 14 '26Sale37.5428,3151,063,03340,000Jul 16 05:14 PM
BRYNJELSEN SEANPresident & CEOJul 14 '26Option Exercise1.37200,000274,0001,061,194Jul 14 05:28 PM
Opaleye Management Inc.10% OwnerJul 02 '26Sale37.3990,0003,364,65960,000Jul 07 06:29 PM
Opaleye Management Inc.10% OwnerJul 07 '26Sale38.3726,6851,023,97853,315Jul 07 06:29 PM
Opaleye Management Inc.10% OwnerJul 06 '26Sale38.0010,000380,0002,700,000Jul 07 06:29 PM
Gruber James R.OfficerJun 26 '26Proposed Sale35.70251,8188,990,000Jun 26 04:14 PM
Gruber James R.OfficerJun 25 '26Proposed Sale35.0125,000875,251Jun 25 04:12 PM
Gruber James R.OfficerJun 23 '26Proposed Sale33.2325,000830,874Jun 23 04:32 PM
Adams Jennifer McKieDirectorJun 17 '26Option Exercise3.7850,000189,00050,000Jun 17 05:08 PM
Adams Jennifer McKieDirectorJun 17 '26Sale32.4850,0001,623,7950Jun 17 05:08 PM
Adams Jennifer McKieDirectorJun 17 '26Proposed Sale32.3750,0001,618,500Jun 17 11:43 AM
Gruber James R.OfficerJun 02 '26Proposed Sale27.003,11784,163Jun 02 04:48 PM
BRYNJELSEN SEANPresident & CEOMay 28 '26Sale31.88120,0003,825,717833,694May 29 04:16 PM
BRYNJELSEN SEANDirectorMay 28 '26Proposed Sale32.40120,0003,888,000May 28 03:12 PM
Krempa DavidChief Business OfficerMay 22 '26Option Exercise3.5830,591109,51668,046May 27 06:28 PM
Krempa DavidChief Business OfficerMay 26 '26Option Exercise1.3837,52451,65862,773May 27 06:28 PM
Krempa DavidChief Business OfficerMay 27 '26Option Exercise2.1819,67942,87944,928May 27 06:28 PM
Krempa DavidChief Business OfficerMay 22 '26Sale33.3942,7971,428,81625,249May 27 06:28 PM
Krempa DavidChief Business OfficerMay 26 '26Sale31.4937,5241,181,73225,249May 27 06:28 PM
Krempa DavidChief Business OfficerMay 27 '26Sale31.4719,679619,37525,249May 27 06:28 PM
Krempa DavidOfficerMay 22 '26Proposed Sale35.00100,0003,500,000May 22 04:24 PM
RIEDEL NORBERT GDirectorApr 21 '26Option Exercise8.1032,155260,60567,155Apr 22 04:40 PM
Krempa DavidOfficerJan 14 '26Proposed Sale15.621,94230,334Jan 14 05:17 PM
Gruber James R.OfficerJan 14 '26Proposed Sale15.472,29335,484Jan 14 05:09 PM
BRYNJELSEN SEANOfficerJan 14 '26Proposed Sale15.395,01577,182Jan 14 11:28 AM
Gruber James R.OfficerDec 12 '25Proposed Sale16.885,45091,996Dec 12 05:11 PM
BRYNJELSEN SEANOfficerDec 12 '25Proposed Sale16.888,035135,631Dec 12 05:05 PM
Erdogan-Trinkaus IpekOfficerDec 12 '25Proposed Sale16.91991,674Dec 12 04:50 PM
Krempa DavidOfficerDec 12 '25Proposed Sale16.887,545127,360Dec 12 04:46 PM
Eton Pharmaceuticals, Inc. engages in the development, acquisition, and commercialization of prescription drug products. Its products include Biorphen, Alaway Preservative Free, zonisamide oral suspension, topiramate oral suspension, lamotrigine for oral suspension, cysteine injection, and ephedrine ready-to-use injection. The company was founded in April 2017 and is headquartered in Deer Park, IL.
PresidentMr. Sean E. Brynjelsen
Chief Business OfficerMr. David C. Krempa
ConsultantMr. James R. Gruber CPA
Chief Commercial OfficerMs. Ipek Erdogan-Trinkaus
Chief Financial Officer & SecretaryMs. Judith M. Matthews
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR
Affiliate • Advertise • APIs • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information
Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)